| Autor: |
Anton Petcherski, Brett M Tingley, Andrew Martin, Sarah Adams, Alexandra J Brownstein, Ross A Steinberg, Byourak Shabane, Gustavo Garcia, Michaela Veliova, Vaithilingaraja Arumugaswami, Aaron H Colby, Orian S Shirihai, Mark W Grinstaff |
| Rok vydání: |
2023 |
| DOI: |
10.1101/2023.05.08.539898 |
| Popis: |
SUMMARYSARS-CoV-2 can infect cells through endocytic uptake, a process which can be targeted by inhibition of lysosomal proteases. However, clinically this approach fared poorly with an oral regimen of hydroxychloroquine that was accompanied by significant toxicity due to off-target effects. We rationalized that an organelle-targeted approach will avoid toxicity while increasing the concentration of the drug at the target. Here we describe a lysosome-targeted, mefloquine-loaded poly(glycerol monostearate-co-ε-caprolactone) nanoparticle (MFQ-NP) for pulmonary delivery via inhalation. Mefloquine is a more effective inhibitor of viral endocytosis than hydroxychloroquine in cellular models of COVID-19. MFQ-NPs are less toxic than molecular mefloquine, 100-150 nm in diameter, and possess a negative surface charge which facilitates uptake via endocytosis allowing inhibition of lysosomal proteases. MFQ-NPs inhibit coronavirus infection in mouse MHV-A59 and human OC43 coronavirus model systems and inhibit SARS-CoV-2-WA1 and its Omicron variant in a human lung epithelium model. This study demonstrates that organelle-targeted delivery is an effective means to inhibit viral infection. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
